Delivery of drug aerosols to the lungs of ventilated neonates by metered dose inhaler and spacer (Aerochamber) and ultrasonic nebuliser (Pentasonic) was assessed using sodium cromoglycate.
Therapeutic aerosols are often used in intubated neonates despite a paucity of information on the pulmonary dose or the most efficient delivery system. A number of devices are available for the production of therapeutic aerosols.
Jet nebulisation is widely used and bronchodilators administered by this method have been shown to improve lung function in intubated infants with bronchopulmonary dysplasia.'
There are, however, problems with jet nebulisation including gas cooling,2 reduction in humidity,3 and a requirement for an auxiliary high pressure gas supply. It is also very inefficient, with 0-2% of the drug dose in the nebuliser reservoir reaching the neonatal lung.4 (fig 3) . The dose of sodium cromoglycate and method of administration were similar to that used in vivo. Inspiratory pressure was set at 20 cm H20 giving a tidal volume to the test lung of 15 ml. After three MDI doses (15 mg), sodium cromoglycate was eluted from the filter with 20 ml water and measured by radioimmunoassay. Particle size The mass median aerodynamic diameter (MMAD) ofparticles generated by the ultrasonic nebuliser was measured by laser diffraction. Ultrasonic aerosol was generated within a con-tinuous 8 I/min airflow which passed through 10 cm of ventilator tubing and 3 5 mm Portex endotracheal tube. Particle size was measured by a laser particle sizer (2600 Malvern Instruments) 2 cm from the endotracheal tube tip.
The MMAD of particles generated by MDI was measured by multistage impactor. Aerosol generated by MDI was carried through the Aerochamber and endotracheal tube by a gas flow of 8 1/min. This was then sucked into a multistage impactor operating at 60 1/min and separated into three size fractions (fig 3) . Sodium cromoglycate deposited in each fraction after 20 doses (100 mg) was assayed by a spectrophotometer that had been previously calibrated using sodium cromoglycate solutions of known concentrations. The total dose deposited within the multistage impactor and The MMAD of particles generated by MDI, after passing through the Aerochamber and endotracheal tube, was 9 0 ,um. MMAD of ultrasonically nebulised sodium cromoglycate after passing through an endotracheal tube was 2-8 ttm (table 4) .
Discussion
The Pentasonic nebuliser and Aerochamber with MDI delivered a detectable dose of sodium cromoglycate to ventilated neonates. A significant proportion of the sodium cromoglycate aerosol generated by both delivery systems was in droplets small enough to penetrate the distal airways. The pulmonary dose of sodium cromoglycate aerosolised by MDI, estimated from the urinary excretion of a known intratracheal dose, was similar to that deposited on a filter model using a neonatal test lung. However, the dose deposited in a multistage impactor significantly overestimated the in vivo dose.
Estimation of the pulmonary dose in vivo depends on the proportion excreted in the urine. Most published data is from adult subjects. Sodium cromoglycate is not metabolised in the lung or liver and is excreted unchanged in the bile and urine.5 Some 70-90% of a 1 mg dose of sodium cromoglycate instilled into the adult lung by fibreoptic bronchoscope will be absorbed into the circulation and of this, 3346% is excreted in the urine.8 9 The plasma half life of either a bronchoscopically instilled or inhaled dose is 64-165 minutes after an initial rapid half life of 1-9 minutes, with lung absorption being the rate limiting step. 8 The pulmonary dose calculated from urinary excretion is similar to that obtained using plasma data. ' (20 mg) were used in vivo, less than 0-1% (20 ,tg) was excreted in the urine of intubated infants.4 A similar overestimate of the in vivo pulmonary dose was obtained by the multistage impactor in our study and may result from incomplete modelling of aerosol behaviour. In a conventional pressure limited, time cycled ventilator, inspiration is a result of the build up of pressure within the circuit from obstructing gas exit while fresh gas in-flow continues. The requirement for a continuous gas flow during the rest of the cycle, means that a significant proportion ofa constantly nebulised drug will be unavailable to the infant. If all the flow through the circuit is directed into a multistage impactor, drug wasted in the expiratory phase in vivo will be collected. There is a similar reason for the overestimation by multistage impactor of the dose delivered by Aerochamber with MDI. Here, the source of error is that the multistage impactor cannot model inspiratory and expiratory flow as aerosol needs to be continuously drawn through the impactor system. The combination of filter and neonatal test lung does model inspiration and expiration and the agreement between the in vivo pulmonary dose (258 ,tg) and sodium cromoglycate deposited on the filter (243 ,ug) after a 15 mg MDI dose reflects this improved modelling.
The filter model also has the advantage that, where aerosol is generated within the continuous gas flow, wastage of drug during expiration is modelled. Filter/test lung models seem to predict accurately jet nebulised aerosol delivery into neonatal ventilator circuits in vivo. Using aminophylline as a drug marker the Ultravent jet nebuliser delivers 0-22% of the reservoir dose to a test lung." A figure of 0 2% has been reported after jet nebulisation in vivo.4 Despite the errors in estimating the pulmonary dose of sodium cromoglycate aerosol, urinary excretion of sodium cromoglycate by the infants in this study reflects the absolute minimum amount of drug delivered to the lung. About 0-7% of the MDI dose and 0-5% of the ultrasonically nebulised dose was excreted in the urine over 24 hours. Although we did not measure it, the deposition of aerosol into the lungs by ultrasonic nebuliser is likely to be dependent on the pattern of mechanical ventilation, as it is for a jet nebuliser inserted into a ventilator circuit. 12 The Pentasonic has not previously been assessed in vivo although the Aerochamber has been used to deliver bronchodilators to intubated adults receiving volume cycled ventilation. An Aerochamber and MDI inserted into the inspiratory limb of a ventilator circuit will deliver 5 7% of the original dose to the adult lung.'3 In adult ventilator circuits, there is no continuous flow and most of the aerosolised drug is delivered to the patient's endotracheal tube. By placing the Aerochamber directly onto the neonate's endotracheal tube the problem of continuous flow is overcome and delivery partially mimics that of the volume cycled ventilator. It may also be possible to enhance ultrasonic drug deposition by placing the nebuliser directly onto the endotracheal tube and ventilating through the chamber.
The therapeutic effectiveness of an aerosol depends not only on the quantity of drug reaching the lung but also on particle size, best described by the MMAD. MMAD is the diameter above and below which 50% of the mass of the particles is found. Particles less than 5 [tm are more likely to deposit in the distal airways whereas larger particles impact on the larger diameterairways. 14 Although the optimum aerosol size for neonates is unknown, theoretical models suggest a similar patterm of deposition to adults. '5 In the past, ultrasonic nebulisers have been bulky and have produced a highly variable output containing significant numbers of large droplets. 6 In this study the combination of both the Pentasonic and Aerochamber with an endotracheal tube produced high quality aerosol. The size distribution of aerosol generated by the Pentasonic was similar to that produced by jet nebulisation. "l The MMAD of particles generated within the Aerochamber was larger (9 ,tm) , as measured by the imperfect multidose impactor model, but a significant proportion of the aerosol was below 5 [lm.
The Pentasonic and the Aerochamber were clinically easy to use. The Aerochamber fitted directly onto the standard Portex endotracheal tube connector without adaption and there were no problems in ventilating infants through the spacer. The Pentasonic could be inserted into the inspiratory line with minimal adaption. There was no change in ventilator pressures during ultrasonic nebulisation and no drop in gas temperature, as measured by a thermister sited in the endotracheal tube connector. It was important to remove the one way valve from the Pentasonic to allow any build up of pressure in the circuit to be vented through the emergency inspiratory blow off valve. The 145 ml Aerochamber temporarily increased the ventilator dead space, and for this reason, we preferred to insert the device briefly, and not to try to maintain mechanical ventilation with the spacer in place. However, spacers are important when using a MDI in ventilator circuits. Particles are ejected from the MDI canister with high velocity and mass.'7 18 As the propellants evaporate particles decrease in size toward the respirable range (<5 [im).'8 If generated near a surface, the large particles will impact and will be wasted. A spacer gives time and distance for particle shrinkage as well as acting as a large particle filter. '" Removing the spacer may shift the impaction of up to 80% of the aerosolised dose from within the device to the endotracheal tube. Although an endotracheal tube may function as a form of spacer," impacted particles may be washed down into the lung during routine nursmg care.
Ultrasonic and MDI aerosolisation have merits and drawbacks. MDIs can effectively aerosolise solutions and suspensions but contain surfactants and propellants, a proportion of which will be deposited within the neonatal lung. MDI drug delivery is also limited by the commercial availability of canisters, but has the potential for rapidly delivering higher doses. Ultrasonic nebulisers can nebulise any solution but is far less efficient in nebulising viscous suspensions such as topical steroids. 20 Therapeutic doses of sodium cromoglycate can be delivered by both systems. In older nonintubated children, 0-26% of a 20 mg dose of sodium cromoglycate generated by MDI 
